Opiates are incredibly potent pain relievers for patients with severe traumatic pain or dealing with end-of-life care, but they are also being increasingly abused. Robert Brooke, the CEO of small cap Vitality Biopharma, Inc. (OTCQB: VBIO), which is dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, has recently written an article entitled: What We Should Know About Opiates and Prescription Drug Abuse.
In the article, Brooke noted a number of interesting statistics about opiates and opiate abuse:
Last year, there were 47,055 Americans that died from drug overdoses, and opioids were involved in 61% of these cases. Since 2013, the rates of drug-overdose deaths have exceeded the number of deaths from car accidents. The U.S. uses 80% of the world’s opioids, while representing only 4.6% of the world’s population. In a movement towards aggressive management of pain, there has been a 10-fold increase in the medical use of opioids in the last 20 years. More than 2.4 million Americans now have a severe opioid-use disorder, which includes dependence on heroin and also prescription opiate drugs that are known by many names. Studies have shown that today about 75% to 86% of heroin users started with prescription opioid pain relievers. A 2012 Canadian study showed that 22% of people who were prescribed opioids by their doctors for long-term pain management started abusing the pills. An estimated 40% of older adults live with chronic pain. Roughly 70% of patients now regularly receive opiates upon hospitalization.
Brooke goes on to write:
Top 5 Medical Stocks To Own Right Now: Amphenol Corporation(APH)
Advisors’ Opinion:
- [By Shane Hupp]
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
Trending Hot Stock’s Analysis – Amphenol Corporation (NYSE:APH) (thestockgem.com) Royal Bank of Canada Raises Amphenol (APH) Price Target to $80.00 (americanbankingnews.com) Analyst Earnings Forecasts Summary: Amphenol Corporation’s (APH) (getstocksnews.com) Global Medical Pressure Sensors Market 2018 Manufacturers- Amphenol, Honeywell, NXP+Freescale and TE … (themobileherald.com) What’s Better? Amphenol Corporation (APH) Buy or Sell (nasdaqfortune.com)
A number of research firms have issued reports on APH. Morgan Stanley raised their price target on shares of Amphenol from $87.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. ValuEngine raised shares of Amphenol from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. SunTrust Banks reissued a “hold” rating and set a $89.00 price target (up from $82.00) on shares of Amphenol in a research report on Thursday, January 25th. Zacks Investment Research lowered shares of Amphenol from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. Finally, Cowen reaffirmed a “buy” rating and set a $105.00 price objective on shares of Amphenol in a research note on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. Amphenol has an average rating of “Buy” and a consensus price target of $92.00.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Amphenol (APH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Amphenol (NYSE:APH) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Amphenol is benefiting from its end-market strength. As evident from fourth-quarter results, revenues are being driven by strong organic growth across mobile devices, military, IT and data communications, mobile networks, commercial air and broadband. Moreover, continuing focus on geographic and market diversification has enabled Amphenol to extend its presence into new customers and new applications. Shares have outperformed the industry in the past year. However, management expects first quarter sales to be negatively impacted by global economic uncertainties related to trade policy and weakness in the mobile devices end market. The geopolitical uncertainty particularly related to the U.S.-China relationship remains a major headwind.”
- [By Max Byerly]
WESPAC Advisors SoCal LLC reduced its position in shares of Amphenol Co. (NYSE:APH) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,725 shares of the electronics maker’s stock after selling 250 shares during the period. WESPAC Advisors SoCal LLC’s holdings in Amphenol were worth $626,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
Greenleaf Trust reduced its holdings in Amphenol (NYSE:APH) by 4.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,234 shares of the electronics maker’s stock after selling 714 shares during the period. Greenleaf Trust’s holdings in Amphenol were worth $1,484,000 as of its most recent SEC filing.
Top 5 Medical Stocks To Own Right Now: SINOPEC Shangai Petrochemical Company Ltd.(SHI)
Advisors’ Opinion:
- [By Stephan Byrd]
Shanghai Petrochemical (NYSE: SHI) and Eastman Chemical (NYSE:EMN) are both basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
- [By Shane Hupp]
SIG (LON:SHI) had its target price dropped by stock analysts at Peel Hunt from GBX 185 ($2.41) to GBX 180 ($2.34) in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the stock. Peel Hunt’s target price would suggest a potential upside of 47.06% from the stock’s current price.
- [By Joseph Griffin]
Press coverage about Shanghai Petrochemical (NYSE:SHI) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shanghai Petrochemical earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the oil and gas company an impact score of 44.8127005121821 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Top 5 Medical Stocks To Own Right Now: Rocky Mountain Chocolate Factory Inc.(RMCF)
Advisors’ Opinion:
- [By Max Byerly]
Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.
- [By Ethan Ryder]
Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.
Top 5 Medical Stocks To Own Right Now: Devon Energy Corporation(DVN)
Advisors’ Opinion:
- [By JJ Kinahan]
Energy was the other S&P sector in the green yesterday, helped by rising oil prices and excitement about the tie up between Marathon Petroleum Corp (NYSE: MPC) and Andeavor (NYSE: ANDV). Devon Energy Corp (NYSE: DVN) was the biggest gainer in the sector, rising more than 5 percent after the company raised its annual production forecast. (See more on oil below.)
- [By Stephan Byrd]
Devon Energy (NYSE:DVN) – Stock analysts at Capital One cut their Q2 2018 EPS estimates for Devon Energy in a report released on Wednesday, June 6th. Capital One analyst P. Johnston now anticipates that the energy company will earn $0.29 per share for the quarter, down from their previous estimate of $0.30. Capital One also issued estimates for Devon Energy’s FY2019 earnings at $2.19 EPS.
- [By Jon C. Ogg]
Devon Energy Corp. (NYSE: DVN) is also a Buy, with a $47 price objective, and with its multiples based on a finite timeline to delivery that is also supported by its core NAV. Shares of Devon Energy were down 0.4% at $29.52.
Top 5 Medical Stocks To Own Right Now: Capital Senior Living Corporation(CSU)
Advisors’ Opinion:
- [By Shane Hupp]
$900.00 upgraded shares of Constellation Software (TSE:CSU) from a neutral rating to an outperform rating in a report issued on Tuesday morning.
Other equities analysts have also issued reports about the stock. National Bank Financial lifted their price target on shares of Constellation Software from C$850.00 to C$875.00 and gave the stock a sector perform rating in a report on Friday, April 27th. CIBC lifted their price target on shares of Constellation Software from C$865.00 to C$900.00 in a report on Friday, April 27th. lifted their price target on shares of Constellation Software to C$980.00 in a report on Thursday, April 26th. Finally, Scotiabank lifted their price target on shares of Constellation Software from C$880.00 to C$940.00 and gave the stock an outperform rating in a report on Tuesday, April 24th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of C$901.88.
- [By Max Byerly]
State of New Jersey Common Pension Fund D lessened its stake in shares of Capital Senior Living (NYSE:CSU) by 5.3% in the first quarter, Holdings Channel reports. The institutional investor owned 180,000 shares of the company’s stock after selling 10,000 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Capital Senior Living were worth $1,935,000 as of its most recent filing with the SEC.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Capital Senior Living (CSU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Media stories about Capital Senior Living (NYSE:CSU) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Capital Senior Living earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.062391046142 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
- [By Logan Wallace]
Barclays reissued their average rating on shares of Capital Senior Living (NYSE:CSU) in a research note released on Monday morning.
Several other equities analysts have also issued reports on the company. ValuEngine lowered Capital Senior Living from a strong-buy rating to a buy rating in a research note on Thursday, December 27th. JMP Securities restated an outperform rating on shares of Capital Senior Living in a research note on Monday, December 31st. Finally, Zacks Investment Research upgraded Capital Senior Living from a hold rating to a buy rating and set a $8.75 price target on the stock in a research note on Monday, January 21st. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Capital Senior Living presently has a consensus rating of Hold and an average price target of $9.38.